Ocumension Therapeutics (5DG.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 05:00PM CEST
| Previous Close | 1.3700 |
| Open | 1.4000 |
| Bid | 1.3900 x 0 |
| Ask | 1.5100 x 0 |
| Day's Range | 1.3900 - 1.4000 |
| 52 Week Range | 0.8950 - 2.4400 |
| Volume | |
| Avg. Volume | 25 |
| Market Cap | 975.566M |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0610 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
WATERTOWN, Mass. and BEIJING, June 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, and OcuMension Therapeutics (HKSE: 1477), a fast-growing ophthalmology focused pharmaceutical company in China, today announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved
© 2022 Yahoo. All rights reserved.
